Alligator Bioscience AB ( (SE:ATORX) ) has shared an update.
Alligator Bioscience announced that CEO Søren Bregenholt will present at BioStock’s ‘Investing in Life Science’ event on 23 September 2025 in Stockholm. The presentation will cover the company’s clinical progress and growth strategy, focusing on mitazalimab, their lead CD40 agonist, and its preparation for Phase 3 trials in metastatic pancreatic cancer. This event is significant for showcasing Alligator’s vision and potential impact on treating hard-to-treat cancers, reinforcing its position in the biotechnology sector.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, specializing in the development of clinical-stage tumor-directed antibody drugs. The company focuses on the CD40 receptor, a validated immuno-oncology approach that enhances T cell priming and counteracts the immunosuppressive tumor microenvironment. Their lead drug candidate, mitazalimab, is poised for Phase 3 development, showing promising results in metastatic pancreatic cancer.
Average Trading Volume: 454,834
Technical Sentiment Signal: Sell
Current Market Cap: SEK143.9M
See more data about ATORX stock on TipRanks’ Stock Analysis page.
Disclaimer & DisclosureReport an Issue